CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:

FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare disease

– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, hea

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and

U.S. stocks closed higher on Wednesday, with the Dow Jones Industrial Average up 0.66% at 46,429.49,

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics sur

U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while T

Sarepta stock jumps after siRNA data show protein reduction, while analysts remain split on outlook

In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle

Sarepta stock slips after FDA update and mixed trial results, as investors weigh approval hopes agai

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperf

– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA b

- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Coho

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises t

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

uniQure (QURE) stock surges following news of CBER director Vinay Prasad's exit. See why the mar

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the a

- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years t

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2

Sarepta's Elevidys shows significant improvement in motor function measures after three years of

Editor’s Note: The future prices of benchmark tracking ETFs,  the lede, the economic data and the he

At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessme

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases

Wedbush analyst Yun Zhong maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and rais

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT)

Gold and silver surged to fresh record highs Monday as investors reassessed the Federal Reserve'

Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases